Based on the latest Barron's, IDIX may move higher or I guess VRTX could and should move lower. Either way, IDIX is dirt cheap with lots of cash, no debt, a great FDA approved product (worth its entire current market cap, IMO) and the furthest along Phase II HCV drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.